Akebia Therapeutics, Inc. (AKBA): Operating Cash Flow
$67.99M
Year ended 2025-12-31
$41.55M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.99M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$40.66M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$23.38M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$73.15M | n/m | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$252.97M | n/m | 2023-08-28, From 2021-01-01 |
| 2020-12-31 | -$110.39M | n/m | 2023-08-28, From 2020-01-01 |
| 2019-12-31 | -$257.44M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$97.49M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$56.16M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $57.91M | n/m | 2019-03-26, From 2016-01-01 |
| 2015-12-31 | -$52.41M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$27.48M | n/m | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | -$11.33M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$7.21M | n/a | 2015-03-04, From 2012-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $67.99M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $19.70M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $107.50M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $41.80M | +7.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$482.00M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$71.10M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $13.90M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$109.44M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $6.73M | n/m |
Compare AKBA, ANAB, KROS, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗